Nucleic acid drugs are one of the most promising fields in the research and development of biomedicine today. At present, there are 16 nucleic acid drugs approved for marketing in the world, including 14 small nucleic acid drugs (3 of which have been withdrawn from the market) and 2 mRNA vaccines. The field of nucleic acid drug indications continues to expand. Small nucleic acid drugs have expanded from genetic diseases to chronic diseases, and mRNA drugs have expanded from preventive infectious vaccines to tumor therapeutic vaccines and protein replacement therapies. At present, nucleic acid drugs are widely used in the treatment of genetic diseases, tumors, viral infections and other diseases. The successful research and development of new technology pathway vaccines represented by nucleic acid vaccines in the COVID-19 epidemic has brought important changes to the vaccine industry. It can be seen that innovative vaccines and multi-unit multivalent vaccines may be the main research and development directions in the future. The innovative vaccines and multi-unit multivalent vaccines that will be launched successively in the future are expected to become blockbuster varieties, bringing expansion to the market size of the global vaccine industry.
There are many patients with potential indications for nucleic acid drugs, and there are huge unmet clinical needs. Technological innovation, favorable policies and active capital have helped China's nucleic acid drug industry to flourish. With the progress in the development of drugs for a wider range of indications in the patient population, it is expected that the global sales of small nucleic acid drugs will exceed 10 billion US dollars in 2025; by 2030, my country's small nucleic acid drug market will also reach 10 billion yuan. According to MarketWatch's research, it is estimated that vaccines using mRNA technology will account for 20%, and mRNA vaccines (excluding COVID-19 vaccines) will reach a market size of US$10.1 billion by 2025. mRNA is expected to bring new solutions in multiple therapeutic areas.
Policies such as the "13th Five-Year Plan for the Development of Bio-industry" clearly stated that the creation and industrialization of biotechnology drugs should be vigorously carried out, and the key development areas include nucleic acid drugs. The "14th Five-Year Plan" for the development of the pharmaceutical industry emphasizes the R&D and capacity building of new vaccines, and supports the construction of technical platforms such as new viral vector vaccines, DNA vaccines, mRNA vaccines, new vaccine adjuvants, and new delivery systems. However, the nucleic acid drug industry still has technical barriers that need to be solved urgently, and faces problems such as molecular stability, immunogenicity, and targeting. As an emerging biotechnology, mRNA vaccines still have high R&D risks.
In this context, the Nucleic Acid Conference 2023 China Nucleic Acid Drug and New Vaccine Industry Conference hosted by Tansi Biotech will be held in Wuhan, China from June 15th to 16th, 2023 . Focusing on core topics such as nucleic acid drug research and development progress, delivery platform, RNA technology, scientific frontiers and basic research, mRNA vaccine research and development progress, exploring more vaccine research and progress, tumor vaccine technology and development, and other core topics, the 1-on-1 communication meeting on R&D and innovation enterprise projects, the sharing of preferential policies in biological parks, etc. will be held at the same time .
Some exciting topics
Innovative GalNac delivery platform targeting
Advances in research and development of small nucleic acid drugs in the field of cardiometabolic
RNA Activation Platform Technology for Rare Disease Drug Development
Functional nucleic acid delivery system based on nucleic acid self-assembly
Noncoding Nucleic Acids and Precision Medicine
Analysis and strategy of high-efficiency and long-acting mRNA delivery technology
How to design and optimize the production of functional IVT mRNA?
Progress in R&D of Peptide Vaccines
New strategy for developing broad-spectrum COVID-19 vaccine
Cancer Vaccine Clinical Development Strategies
Some past speakers
Professor Li Yaping, Director, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Dr. Gao Shan, Senior Deputy General Manager/CSO, Suzhou Ruibo Biotechnology Co., Ltd.
Professor Liu Binlei, Chairman and General Manager of Wuhan Binhui Biotechnology Co., Ltd.
Professor Fei Jia, Jinan University, Professor of Department of Biochemistry, School of Basic Medical Sciences, doctoral supervisor
Dr. Shenggao Tang, General Manager of Sino Biomedical Technology (Guangzhou) Co., Ltd.
Dr. Laixin Wang, Executive Vice President/CSO, Chongqing Denali Pharmaceutical Technology Co., Ltd.
Dr. Yang Naibo, Chief Operating Officer, BGI Genoin Biotechnology Co., Ltd.
Dr. Wang Haomeng, CanSino Biologics (Shanghai) Co., Ltd., Deputy General Manager
Dr. Xiao Xiao, Jiangsu Shenji Biotechnology Co., Ltd., Co-Founder
Dr. Ales Štrancar, Founder and Chief Executive Officer, BIA Separations doo
Dr. Xu Long, Wuhan Bovo Biotechnology Co., Ltd., senior project manager
Dr. Juan Liu, Zhejiang Haichang Biomedical Technology Co., Ltd., Senior Researcher
Dr. Jin Qiuheng, Nanjing Novazyme Biotechnology Co., Ltd., R&D Director of Biomedical Division
Dr. Jia Zhang, Agilent Technologies, Product Manager
Dr. Lang Shiwei, Director of Macromolecular Bioanalysis Department, Wuhan Hongren Biomedical Co., Ltd.
Ms. Li Jiachang, TiPLab, Patent Search Expert Technical Analyst
Mr. Liu Weiqi, Frost & Sullivan, Executive Director
Dr. Zhao Xin, Founder of Guite (Beijing) Pharmaceutical Technology Co., Ltd.
Part of the previous participating companies
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, National Nanoscience Center, Wuhan Institute of Biotechnology, Tsinghua Institute of Technology Cell and Gene Therapy Innovation Center (CGTIC), China Pharmaceutical University, Wuhan University Medical Research Institute, Ruibo Bio, Ceno Bio, Binhui Bio, Bovo Bio, CanSino Bio, Haichang Bio, Kexing Biopharmaceuticals, Gemma Gene, Huada Gene, Boya Gene, Bangyao Biology, Grand Pharmaceutical, Buchang Pharmaceutical, Dabo Biology, Guowei Biology, Hanchen Biology, Hetang Shenghua, Huada Genoin, Kinsey Pharmaceuticals, Bowei Biologicals, Renfu Pharmaceuticals, Shengyin Biopharmaceuticals, Shutong Medical, Tibet Weixinkang Pharmaceuticals, Asymchem Pharmaceuticals, WuXi AppTec, Difulunsi Biological, Heyan Biological, Huaxi Haiqi, Hunda Biological, Medicilon, Zhengji Pharmaceuticals, Tigermed, Tiangen Biological, Youwei Biological, Roche Diagnostics, General Biology, Tangzhi Pharmaceuticals, Weihuan Biological, Maiana Instruments, Ruibeixi Biological, Quanhecheng Technology, Kangwei Century Biological, Xavier Biological, Titan Technology, Haixin Enzyme, Heyuan Bio, Huiyan Bio, Research Assistant Medicine, etc...
Nucleic acid meeting 2022 exciting scene